Importance of correct management of bisphosphonate-related osteonecrosis of the jaw
case report and literature review
DOI:
https://doi.org/10.5935/2525-5711.20180008Keywords:
Bisphosphonate-associated osteonecrosis of the jaw, Osteonecrosis, Diagnosis, Treatment OutcomeAbstract
Introduction: Osteonecrosis results from local and systemic factors that compromise blood flow in bone tissues, being relatively frequent in maxillary bones. In recent years, there has been an increase in the incidence of new cases of medication-related osteonecrosis of the jaw (MRONJ). Objective: The aim of this study is to report a case of hard palate osteonecrosis associated with the use of bisphosphonate and to review the literature on the major clinical features, diagnosis, and management of this disorder. Case report: An 84-year-old female patient presented with a lesion to the midline of the hard palate with exposed necrotic bone. Family members reported that the patient had been on ibandronate sodium for nearly 5 years. Based on clinical and radiographic findings, the diagnosis indi-cated MRONJ. The patient underwent a surgical procedure for debridement of necrotic bone and closure of the exposed tissue by means of Z-plasty. After a 4-month follow-up, there were no clinical and radiographic signs of recurrence. Conclusion: The present case and the literature highlight the importance of proper anamnesis combined with clinical, radiographic, and laboratory findings to make an accurate diagnosis in order to provide the best therapeutic approach. In addition, the importance of dental surgeons knowledge aboutthe association between bisphosphonate therapy and osteonecrosis is very important, given the several indications of this drug and, thus, the high probability of attending to patients treated with this medication, with the aim of reducing the occurrence of new cases of MRONJ and, consequently, morbidities and their aggravation.
References
Brozoski MA, Traina AA, Deboni MC, Marques MM, Naclério-Homem Mda G. Bisphosphonate-related osteonecrosis of the jaw. Rev Bras Reumatol. 2012;52:265-70.
Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate-related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. Int J Oral Maxillofac Surg. 2015;44:568-85.
Fung PL, Nicoletti P, Shen Y, Porter S, Fedele S. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw. Oral Maxillofac Surg Clin North Am. 2015;27:537-46.
Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al.; International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015;30:3-23.
Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al.; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22:1479-91.
Pichardo SE, Kuijpers SC, van Merkesteyn JP. Bisphosphonate-related osteonecrosis of the jaws: Cohort study of surgical treatment results in seventy-four stage II/III patients. J Craniomaxillofac Surg. 2016;44:1216-20.
Zandi M, Dehghan A, Janbaz P, Malekzadeh H, Amini P. The starting point for bisphosphonate-related osteonecrosis of the jaw: Alveolar bone or oral mucosa? A randomized, controlled experimental study. J Craniomaxillofac Surg. 2017;45:157-61.
Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimitrakopoulos I, Antoniadis K, et al. Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol. 2007;28:158-63.
Ruggiero SL. Emerging concepts in the management and treatment of osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2013;25:11-20.
Paiva-Fonseca F, Santos-Silva AR, Della-Coletta R, Vargas PA, Lopes MA. Alendronate-associated osteonecrosis of the jaws: a review of the main topics. Med Oral Patol Oral Cir Bucal. 2014;19:e106-11.
Mücke T, Krestan CR, Mitchell DA, Kirschke JS, Wutzl A. Bisphosphonate and Medication-Related Osteonecrosis of the Jaw: A Review. Semin Musculoskelet Radiol. 2016;20:305-14.
Bodem JP, Schaal C, Kargus S, Saure D, Mertens C, Engel M, et al. Surgical management of bisphosphonate-related osteonecrosis of the jaw stages II and III. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;121:367-72.
Bermúdez-Bejarano EB, Serrera-Figallo MA, Gutiérrez-Corrales A, Romero-Ruiz MM, Castillo-de-Oyagüe R, Gutiérrez-Pérez JL, et al. Analysis of different therapeutic protocols for osteonecrosis of the jaw associated with oral and intravenous bisphosphonates. Med Oral Patol Oral Cir Bucal. 2017;22:43-57.
Russell RG. Bisphosphonates: the first 40 years. Bone. 2011;49:2-19.
Goodday RH. Preventive Strategies for Patients at Risk of Medication-related Osteonecrosis of the Jaw. Oral Maxillofac Surg Clin North Am. 2015;27:527-36.
Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al.; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014;72:1938-56.
Ito M, Chokki M, Ogino Y, Satomi Y, Azuma Y, Ohta T, et al. Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo. Calcif Tissue Int. 1998;63:143-7.
Aghaloo T, Hazboun R, Tetradis S. Pathophysiolog y of Osteonecrosis of the Jaws. Oral Maxillofac Surg Clin North Am. 2015;27:489-96.
Arce K, Assael LA, Weissman JL, Markiewicz MR. Imaging findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg. 2009;67(5 Suppl):75-84.
Klingelhöffer C, Klingelhöffer M, Müller S, Ettl T, Wahlmann U. Can dental panoramic radiographic findings serve as indicators for the development of medication-related osteonecrosis of the jaw? Dentomaxillofac Radiol. 2016;45:20160065.
Yarom N, Goss A, Lazarovici TS, Elad S. Bisphosphonate-Related Osteonecrosis of the Jaw. J Am Dent Assoc. 2016;147:776-7.
Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397-410.
Fleisher KE, Welch G, Kottal S, Craig RG, Saxena D, Glickman RS. Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:509-16.
Garnero P. New developments in biological markers of bone metabolism in osteoporosis. Bone. 2014;66:46-55.
Wutzl A, Pohl S, Sulzbacher I, Seemann R, Lauer G, Ewers R, et al. Factors influencing surgical treatment of bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2012;34:194-200.
Lopes RN, Rabelo GD, Rocha AC, Carvalho PA, Alves FA. Surgical Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw: Six-Year Experience of a Single Institution. J Oral Maxillofac Surg. 2015;73:1288-95.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 1969 Cristianne Kalinne Santos Medeiros, Hellen Bandeira de Pontes Santos, Larissa Santos Amaral Rolim, Antonio Bruno Gomes Mororó, Adriano Rocha Germano, Ana Miryam Costa de Medeiros, Patrícia Teixeira de Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
